The announcement of presenting new data at a significant industry conference like AACR 2024 can be seen as a positive development for Biodesix. It not only showcases the company's commitment to advancing cancer diagnostics but also potentially positions Biodesix as a leader in the liquid biopsy technology space. This could lead to increased investor interest and potentially positive movement in BDSX's stock price in the short term, as the market reacts to the potential implications of these advancements for the company's product offerings and market position.